Multiple Sclerosis Clinical Trial
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Summary
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis
Full Description
The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.
Eligibility Criteria
Inclusion Criteria:
18 to 55 years of age
Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
EDSS score of 0 to 5.5 (inclusive)
Neurologically stable within 1 month
Exclusion Criteria:
Diagnosis of primary progressive multiple sclerosis (PPMS)
Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
History of clinically significant CNS disease other than MS
Ongoing substance abuse (drug or alcohol)
History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
suicidal ideation or behavior
Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
Participants who have had a splenectomy
Active clinically significant systemic bacterial, viral, parasitic or fungal infections
Positive results for syphilis or tuberculosis testing
Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or participants with moderate or severe hepatic impairment (Child-Pugh class C) or any chronic liver or biliary disease.
History of severe renal disease or creatinine level
Participants at risk of developing or having reactivation of hepatitis
Hematology parameters at screening:
Hemoglobin: < 10 g/dl (<100g/L)
Platelets: < 100000/mm3 (<100 x 109/L)
Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
White blood cells: <3 000/mm3 (<3.0 x 109/L)
Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
History or current diagnosis of significant ECG abnormalities
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment (prior to randomization)
Use of other investigational drugs
Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
History of gastrointestinal bleeding
Major surgery within 8 weeks prior to screening
History of hypersensitivity to any of the study drugs or excipients
Pregnant or nursing (lactating) female participants, prior to randomization
Women of childbearing potential not using highly effective contraception
Sexually active males not agreeing to use condom
Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization
Inclusion to Extension part:
• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)
Other inclusion and exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 223 Locations for this study
Phoenix Arizona, 85018, United States More Info
Principal Investigator
Hanford California, 93230, United States More Info
Principal Investigator
West Hollywood California, 90048, United States More Info
Principal Investigator
Aurora Colorado, 80045, United States More Info
Principal Investigator
Colorado Springs Colorado, 80907, United States More Info
Principal Investigator
Denver Colorado, 80210, United States More Info
Principal Investigator
Washington District of Columbia, 20007, United States More Info
Principal Investigator
Boca Raton Florida, 33487, United States More Info
Principal Investigator
Bradenton Florida, 34209, United States More Info
Principal Investigator
Gainesville Florida, 32610, United States More Info
Principal Investigator
Hollywood Florida, 33021, United States More Info
Principal Investigator
Maitland Florida, 32751, United States More Info
Principal Investigator
Miami Florida, 33136, United States More Info
Principal Investigator
Naples Florida, 34102, United States More Info
Principal Investigator
Orlando Florida, 32803, United States More Info
Principal Investigator
Pembroke Pines Florida, 33024, United States More Info
Principal Investigator
Pensacola Florida, 32514, United States More Info
Principal Investigator
Port Orange Florida, 32127, United States More Info
Principal Investigator
Vero Beach Florida, 32960, United States More Info
Principal Investigator
Winter Park Florida, 32789, United States More Info
Principal Investigator
Suwanee Georgia, 30024, United States More Info
Principal Investigator
Merrillville Indiana, 46410, United States More Info
Principal Investigator
Kansas City Kansas, 66160, United States More Info
Principal Investigator
Nicholasville Kentucky, 40356, United States More Info
Principal Investigator
New Orleans Louisiana, 70121, United States More Info
Principal Investigator
Frederick Maryland, 21702, United States More Info
Principal Investigator
Boston Massachusetts, 02111, United States More Info
Principal Investigator
Owosso Michigan, 48867, United States More Info
Principal Investigator
Kansas City Missouri, 64128, United States More Info
Principal Investigator
Patchogue New York, 11772, United States More Info
Principal Investigator
Charlotte North Carolina, 28210, United States More Info
Principal Investigator
Columbus Ohio, 43235, United States More Info
Principal Investigator
Dayton Ohio, 45408, United States More Info
Principal Investigator
Charleston South Carolina, 29425, United States More Info
Principal Investigator
Greenville South Carolina, 29650, United States More Info
Principal Investigator
Indian Land South Carolina, 29707, United States More Info
Principal Investigator
Knoxville Tennessee, 37922, United States More Info
Principal Investigator
Dallas Texas, 75231, United States More Info
Principal Investigator
El Paso Texas, 79935, United States More Info
Principal Investigator
Frisco Texas, 75035, United States More Info
Principal Investigator
Houston Texas, 77094, United States
San Antonio Texas, 78229, United States More Info
Principal Investigator
San Antonio Texas, 78258, United States More Info
Principal Investigator
Sherman Texas, 75092, United States More Info
Principal Investigator
Seattle Washington, 98101, United States More Info
Principal Investigator
Seattle Washington, 98133, United States More Info
Principal Investigator
Crab Orchard West Virginia, 25827, United States More Info
Principal Investigator
Green Bay Wisconsin, 54311, United States More Info
Principal Investigator
Milwaukee Wisconsin, 53226, United States More Info
Principal Investigator
Caba Buenos Aires, C1181, Argentina
Bombal Mendoza, M5500, Argentina
Rosario Santa Fe, S2000, Argentina
Rosario Santa Fe, S2000, Argentina
San Miguel De Tucuman, T4000, Argentina
Buenos Aires , C1012, Argentina
Brasilia DF, 70200, Brazil
Vitoria ES, 29055, Brazil
Curitiba PR, 81210, Brazil
Porto Alegre Rio Grande Do Sul, 90035, Brazil
Porto Alegre RS, 90110, Brazil
Porto Alegre RS, 90430, Brazil
Joinville Santa Catarina, 89202, Brazil
Sao Paulo , 01240, Brazil
Plovdiv , 4002, Bulgaria
Sofia , 1309, Bulgaria
Sofia , 1407, Bulgaria
Sofia , 1413, Bulgaria
Edmonton Alberta, T6G 2, Canada
Burnaby British Columbia, V5G 2, Canada
Halifax Nova Scotia, B3H 4, Canada
Ottawa Ontario, K1H 8, Canada
Greenfield Park Quebec, J4V 2, Canada
Levis Quebec, G6W 0, Canada
Montreal Quebec, H4A 3, Canada
St Jerome Quebec, J7Z 5, Canada
Quebec , G1J 1, Canada
Fuzhou Fujian, 35002, China
Wuhan Hubei, 43003, China
Wuhan Hubei, 43006, China
Nanjing Jiangsu, 21002, China
Yinchuan Ningxia, 10003, China
Taiyuan Shanxi, 03000, China
Hangzhou Zhejiang, 31000, China
Hangzhou Zhejiang, 31001, China
Wenzhou Zhejiang, 32500, China
Beijing , 10003, China
Shanghai , 20002, China
Shanghai , 20004, China
Split HRV, 21000, Croatia
Varazdin HRV, 42000, Croatia
Vukovar , 32000, Croatia
Zagreb , 10000, Croatia
Tallinn , 11315, Estonia
Tartu , 50406, Estonia
Nantes Cedex 1, 44093, France
Toulon Cedex 9 Val De Marne, 83800, France
Caen , 14033, France
Clermont-Ferrand Cedex 1 , 63003, France
Contamine Sur Arve , 74130, France
Dijon , 21034, France
Gonesse , 95500, France
Grenoble , 38042, France
Lille , 59000, France
Lille , 59037, France
Limoges , 87042, France
Marseille , 13003, France
Nice , 06202, France
Nimes , 30029, France
Poissy , 78303, France
Suresnes , 92150, France
Toulouse Cedex 9 , 31059, France
Athens Attica, 11526, Greece
Ioannina GR, 455 0, Greece
Larissa GR, 411 1, Greece
Athens , 115 2, Greece
Athens , 12462, Greece
Greece , 53246, Greece
Thessaloniki , GR 54, Greece
New Delhi Delhi, 110 0, India
Kochi Kerala, 68202, India
Pune Maharashtra, 41100, India
Pune Maharashtra, 41101, India
Amritsar Punjab, 14300, India
Hyderabad Telangana, 50008, India
Lucknow Uttar Pradesh, 22600, India
Kolkata West Bengal, 70001, India
Brindisi BR, 72100, Italy
Foggia FG, 71100, Italy
Firenze FI, 50134, Italy
Pozzilli IS, 86077, Italy
Messina ME, 98121, Italy
Modena MO, 41126, Italy
Pavia PV, 27100, Italy
Orbassano TO, 10043, Italy
Napoli , 80131, Italy
Nagoya Aichi, 466 8, Japan
Ichihara-city Chiba, 299-0, Japan
Fukuoka city Fukuoka, 812-8, Japan
Koriyama city Fukushima, 963-8, Japan
Sapporo city Hokkaido, 063-0, Japan
Kobe-shi Hyogo, 650-0, Japan
Nishinomiya Hyogo, 663 8, Japan
Isehara Kanagawa, 259-1, Japan
Sagamihara Kanagawa, 252-0, Japan
Kyoto-city Kyoto, 616-8, Japan
Sendai city Miyagi, 983 8, Japan
Kashihara city Nara, 634 8, Japan
Moriguchi Osaka, 570-8, Japan
Suita Osaka, 565 0, Japan
Higashimatsuyama Saitama, 355-0, Japan
Itabashi-ku Tokyo, 173-8, Japan
Kodaira Tokyo, 187-8, Japan
Shinjuku-ku Tokyo, 160 8, Japan
Shinjuku-ku Tokyo, 160-0, Japan
Chiba , 26086, Japan
Fukuoka , 810-0, Japan
Niigata , 951 8, Japan
Ciudad de Mexico Distrito Federal, 06700, Mexico
Chihuahua , 31203, Mexico
Ciudad De Mexico , 14050, Mexico
Queretaro , 76070, Mexico
Plewiska Poznan, 62-06, Poland
Bialystok , 15-70, Poland
Glogow , 36-06, Poland
Katowice , 40 57, Poland
Katowice , 40-08, Poland
Katowice , 40-12, Poland
Krakow , 31-63, Poland
Wroclaw , 51-68, Poland
Zabrze , 41-80, Poland
Matosinhos Porto, 44545, Portugal
Braga , 47102, Portugal
Coimbra , 3000 , Portugal
Leiria , 2410-, Portugal
Lisboa , 1169 , Portugal
Lisboa , 1649 , Portugal
Santa Maria da Feira , 4520 , Portugal
Guaynabo , 00968, Puerto Rico More Info
Principal Investigator
Brasov ROM, 50012, Romania
Campulung Muscel ROM, 11510, Romania
Constanta ROM, 90012, Romania
Constanta , 90059, Romania
Suceava , 72752, Romania
Targu Mures , 54013, Romania
Banska Bystrica , 974 0, Slovakia
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.